JPMorgan Upgrades Teva Pharma (TEVA) to Neutral, 'we remain cautious'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Teva Pharma (TEVA) PT Raised to $17 at Jefferies, 'Innovation Strategy Resonating'
March 11, 2024 12:31 PM EDTJefferies analyst Glen Santangelo raised the price target on Teva Pharma (NYSE: TEVA) to $17.00 (from $16.00) while maintaining a Buy rating.
The analyst comments "We hosted TEVA CEO, CFO, CMO and IR for mtgs and think that while the co is clearly... More
